Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in east Africa

JAMA - Journal of the American Medical Association

Volumn 317, Issue 21, 2017, Pages 2196-2206

  Petersen, Maya ^a   Balzer, Laura ^b,c   Kwarsiima, Dalsone ^d   Sang, Norton ^e   Chamie, Gabriel ^b   Ayieko, James ^e   Kabami, Jane ^d   Owaraganise, Asiphas ^d   Liegler, Teri ^b   Mwangwa, Florence ^d   Kadede, Kevin ^f   Jain, Vivek ^b   Plenty, Albert ^b   Brown, Lillian ^b   Lavoy, Geoff ^d   Schwab, Joshua ^a   Black, Douglas ^b   Van Der Laan, Mark ^a   Bukusi, Elizabeth A ^e   Cohen, Craig R ^b   Clark, Tamara D ^b   Charlebois, Edwin ^b   Kamya, Moses ^d   Havlir, Diane ^b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; LAMIVUDINE; VIRUS RNA;

ADOLESCENT; ADULT; AFRICA; AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY; ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DOCTOR PATIENT RELATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PREVALENCE; PRIORITY JOURNAL; RURAL AREA; TREATMENT PLANNING; UGANDAN; VIRUS REPLICATION; BLOOD; COMMUNITY CARE; HIV INFECTIONS; HIV SEROPOSITIVITY; ISOLATION AND PURIFICATION; KENYA; MIDDLE AGED; RURAL POPULATION; UGANDA; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; COMMUNITY HEALTH SERVICES; FEMALE; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; KENYA; MALE; MIDDLE AGED; RNA, VIRAL; RURAL POPULATION; UGANDA; VIRAL LOAD; YOUNG ADULT;

EID: 85020410653     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.5705     Document Type: Article

References (40)

1. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al.; HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014; 14(4): 281-290.
2. Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365 (6): 493-505.
3. Lundgren JD, Babiker AG, Gordin F, et al.; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373(9): 795-807.
4. Granich RM, Gilks CF, Dye C, DeCock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009; 373(9657): 48-57.
5. Walensky RP, Borre ED, Bekker LG, et al. The anticipated clinical and economic effects of 90-90-90in South Africa. Ann Intern Med. 2016; 165(5): 325-333.
6. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013; 339(6122): 966-971.
7. Stover J, Hallett TB, Wu Z, et al.; New Prevention Technology Study Group. How can we get close to zero? the potential contribution of biomedical prevention and the investment framework towards an effective response to HIV. PLoS One. 2014; 9(11): e111956.
8. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/sites/default/files/media-asset/90-90-90-en.pdf. Accessed May 8, 2017.
9. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: What's New: November 2015. Geneva, Switzerland: World Health Organization; 2015.
10. Gaolathe T, Wirth KE, Holme MP, et al.; Botswana Combination Prevention Project study team. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016; 3(5): e221-e230.
11. Levi J, Raymond A, Pozniak A, Vernazza PL, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be reached? a systematic analysis of national HIV treatment cascades. BMJ Global Health. 2016; 1(2): e000010. doi: 10.1136/bmjgh-2015-000010
12. Granich R, Gupta S, Hall I, Aberle-Grasse J, Hader S, Mermin J, Egger M. Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review. PLoS Med. 2017; 14(4): e1002253.
13. Cherutich P, Kim AA, Kellogg TA, et al. Detectable HIV viral load in Kenya: data from a population-based survey. PLoS One. 2016; 11(5): e0154318.
14. Adakun SA, Siedner MJ, Muzoora C, et al. Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr. 2013; 62(3): 317-321.
15. Tenthani L, Haas AD, Tweya H, et al.; Ministry of Health in Malawi and IeDEA Southern Africa. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (Option B+) in Malawi. AIDS. 2014; 28(4): 589-598.
16. Chamie G, Clark TD, Kabami J, et al. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016; 3(3): e111-e119.
17. Ayieko J, Van Rie A, Owaraganise A, et al. A novel strategy for accelerated linkage to care following community-wide HIV testing. Poster presented at: International AIDS Conference; July 18-22, 2016; Durban, South Africa.
18. Kwarisiima D, Jain V, Owaraganise A, et al. Virologic efficacy, safety, and retention in adults starting ART at high CD4 with streamlined care in rural Africa. Oral presentation at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
19. Jain V, Liegler T, Kabami J, et al.; SEARCH Collaboration. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013; 56(4): 598-605.
20. Balzer L, Schwab J, van der Laan M, Petersen M. Evaluation of progress towards the UNAIDS 90-90-90 HIV care cascade: a description of statistical methods used in an interim analysis of the intervention communities in the SEARCH Study. http://biostats.bepress.com/cgi/viewcontent.cgi?article=1365&context=ucbbiostat. Accessed May 8, 2017.
21. van der Laan MJ, Gruber S. Targeted minimum loss based estimation of causal effects of multiple time point interventions. Int J Biostat. 2012; 8(1): 8.
22. van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol. 2007; 6: e25.
23. Polley EC, van der Laan M. SuperLearner: super learner prediction: R package, version 2.0-21. http://cran.r-project.org/web/packages/SuperLearner/index.html. Accessed May 8, 2017.
24. R Core Team. R: a language and environment for statistical computing. http://www.R-project.org/. Accessed May 8, 2017.
25. Schwab J, Lendle S, Petersen M, Gruber S, van der Laan M. ltmle: Longitudinal targeted maximum likelihood estimation. http://cran.r-project.org/web/packages/ltmle/. Accessed May 8, 2017.
26. Jain V, Petersen ML, Liegler T, et al.; SEARCH Collaboration. Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis. Lancet HIV. 2017; 4(3): e122-e133.
27. Losina E, Bassett IV, Giddy J, et al. The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One. 2010; 5(3): e9538.
28. Geng EH, Odeny TA, Lyamuya R, et al.; East Africa International Epidemiologic Databases to Evaluate AIDS Consortium. Retention in care and patient-reported reasons for undocumented transfer or stopping care among HIV-infected patients on antiretroviral therapy in Eastern Africa: application of a sampling-based approach. Clin Infect Dis. 2016; 62(7): 935-944.
29. Henry J. Kaiser Family Foundation. Financing theresponsetoAIDSin low- and middle-income countries: international assistance from donor governments in 2014. https://kaiserfamilyfoundation.files.wordpress.com/2015/06/7347-11-financing-the-response-to-aids-in-low-and-middle-income-countries.pdf. Accessed May 8, 2017.
30. Hodgson I, Plummer ML, Konopka SN, et al. A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women. PLoS One. 2014; 9(11): e111421.
31. Treves-Kagan S, Steward WT, Ntswane L, et al. Why increasing availability of ART is not enough: a rapid, community-based study on how HIV-related stigma impacts engagement to care in rural South Africa. BMC Public Health. 2016; 16: 87.
32. Kranzer K, Lawn SD, Johnson LF, Bekker LG, Wood R. Community viral load and CD4 count distribution among people living with HIV in a South African township: implications for treatment as prevention. J Acquir Immune Defic Syndr. 2013; 63(4): 498-505.
33. Maman D, Zeh C, Mukui I, et al. Cascade of HIV care and population viral suppression in a high-burden region of Kenya. AIDS. 2015; 29(12): 1557-1565.
34. Lippman SA, Shade SB, El Ayadi AM, et al. Attrition and opportunities along the HIV care continuum: findings from a population-based sample, North West Province, South Africa. J Acquir Immune Defic Syndr. 2016; 73(1): 91-99.
35. Maman D, Chilima B, Masiku C, et al. Closer to 90-90-90: the cascade of care after 10 years of ART scale-up in rural Malawi: a population study. J Int AIDS Soc. 2016; 19(1): 20673.
36. Justman J, Hoos D, Kalton G, et al. 114LB: Real progress in the HIV epidemic: PHIA findings from Zimbabwe, Malawi, and Zambia. Abstract presented at: Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, WA.
37. Grabowski M, Nakigozi G, Nalugoda F, et al. 34LB Combination HIV prevention and HIV incidence in Rakai, Uganda. Abstract presented at: Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, WA.
38. Larmarange J, Iwuji C, Orne-Gliemann J, et al. Measuring the impact of test and treat on the HIV cascade: the challenge of mobility. Abstract presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
39. International AIDS Society. Differentiated care for HIV: a decision framework for antiretroviral therapy delivery. http://www.differentiatedcare.org/Portals/0/adam/Content/yS6M-GKB5EWs-uTBHk1C1Q/File/Decision%20Framework.pdf. Accessed May 8, 2017.
40. UNAIDS. Fast track: ending the AIDS epidemic by 2030. http://www.unaids.org/sites/default/files/media-asset/JC2686-WAD2014report-en.pdf. Accessed May 8, 2017.